Journal article
The significance of FOXP1 in diffuse large B-cell lymphoma
- Abstract:
-
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of mature B-cell lymphoma. While the majority of patients are cured with immunochemotherapy incorporating the anti-CD20 monoclonal antibody rituximab (R-CHOP), relapsed and refractory patients still have a dismal prognosis. DLBCL subtypes including an aggressive activated B-cell-like (ABC) and a more favourable prognosis germinal centre-like (GCB) DLBCL have been identified by gene expression profiling and are characterised by d...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Accepted manuscript, pdf, 1.5MB)
-
- Publisher copy:
- 10.1080/10428194.2016.1228932
Authors
Funding
+ Bloodwise Specialist Programme grant
More from this funder
Funding agency for:
Banham, A
Grant:
13047
Bibliographic Details
- Publisher:
- Taylor and Francis Publisher's website
- Journal:
- Leukemia and Lymphoma Journal website
- Volume:
- 58
- Issue:
- 5
- Pages:
- 1037-1051
- Publication date:
- 2016-09-01
- Acceptance date:
- 2016-08-23
- DOI:
- EISSN:
-
1029-2403
- ISSN:
-
1042-8194
- Source identifiers:
-
641717
Item Description
- Pubs id:
-
pubs:641717
- UUID:
-
uuid:0af296cc-ed42-4dea-8457-9dc26cb1c00a
- Local pid:
- pubs:641717
- Deposit date:
- 2016-09-08
Terms of use
- Copyright holder:
- Gascoyne and Banham
- Copyright date:
- 2016
- Notes:
- © 2016 The Author(s). Published by Informa UK Limited, trading as Taylor and Francis Group.This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unre-stricted use, distribution, and reproduction in any medium, provided the original work is properly cited
If you are the owner of this record, you can report an update to it here: Report update to this record